Results 191 to 200 of about 1,443,667 (357)

ANTIPASTI: interpretable prediction of antibody binding affinity exploiting Normal Modes and Deep Learning [PDF]

arXiv
The high binding affinity of antibodies towards their cognate targets is key to eliciting effective immune responses, as well as to the use of antibodies as research and therapeutic tools. Here, we propose ANTIPASTI, a Convolutional Neural Network model that achieves state-of-the-art performance in the prediction of antibody binding affinity using as ...
arxiv  

Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody [PDF]

, 2004
Fabrice Le Gall, Uwe Reusch, Melvyn Little, Sergey M. Kipriyanov   +3 more
openalex   +1 more source

Head‐To‐Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?

Allergy, EarlyView.
ABSTRACT We performed an in‐depth appraisal of indirect head‐to‐head comparisons of biologics approved for asthma, including anti‐IL5/5Rα (mepolizumab, benralizumab), anti‐IL4Rα (dupilumab), anti‐TSLP (tezepelumab) and anti‐IgE (omalizumab), which was neither a systematic review nor a meta‐analysis.
Brian J. Lipworth, Robert Greig, Rory Chan, Chris RuiWen Kuo, Catherine Jackson   +4 more
wiley   +1 more source

Precise Antigen-Antibody Structure Predictions Enhance Antibody Development with HelixFold-Multimer [PDF]

arXiv
The accurate prediction of antigen-antibody structures is essential for advancing immunology and therapeutic development, as it helps elucidate molecular interactions that underlie immune responses. Despite recent progress with deep learning models like AlphaFold and RoseTTAFold, accurately modeling antigen-antibody complexes remains a challenge due to
arxiv  

A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells [PDF]

, 2004
Joerg Bruenke, Barbara Fischer, Karin Barbin, Katja Schreiter, Yvonne Wachter, Kerstin Mahr, Fritz Titgemeyer, Michael Niederweis, Matthias Peipp, Susan J. Zunino, Roland Repp, Thomas Valerius, Georg H. Fey   +12 more
openalex   +1 more source

In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B‐cell lymphoma (DLBCL) cell lines with different levels of expression of CD20

British Journal of Haematology, EarlyView.
Summary Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B‐cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ...
Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Adam Wright, Sandrine Jayne, Martin J. S. Dyer, Harriet S. Walter   +6 more
wiley   +1 more source

A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression

Scientific Reports
The bispecific antibody IMV-M was designed to selectively bind and cluster death receptor 5 (DR5) upon engaging the tumor antigen MUC16 through a novel mechanism—clustering multiple IMV-M molecules on a single MUC16 molecule.
Victor S. Goldmacher, Iosif Gershteyn, Ravi Chari, Yelena Kovtun   +3 more
doaj   +1 more source

AlignAb: Pareto-Optimal Energy Alignment for Designing Nature-Like Antibodies [PDF]

arXiv
We present a three-stage framework for training deep learning models specializing in antibody sequence-structure co-design. We first pre-train a language model using millions of antibody sequence data. Then, we employ the learned representations to guide the training of a diffusion model for joint optimization over both sequence and structure of ...
arxiv  

Use of Bispecific Antibodies in Molecular Velcro Assays Whose Specificity Approaches the Theoretical Limit of Immunodetection for Bordetella pertussis [PDF]

, 2004
Xinling L. Tang, M S Peppler, Randall T. Irvin, M.R. Suresh   +3 more
openalex   +1 more source

Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases

British Journal of Haematology, EarlyView.
Summary Glofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated faecal calprotectin, abnormal bowel avidity on positron emission tomography scan (2/3 ...
Sean McKeague, Molly Robertson, Sam van der Linde, Christine Khoo, Jonathan Segal, Sean Harrop, Adrian Minson, Andrew W. Roberts, Michael Dickinson   +8 more
wiley   +1 more source